Jan 19 (Reuters) - The U.S. Supreme Court on Tuesday
rejected Merck & Co Inc's bid to revive a $2.54 billion
jury verdict it won against rival drugmaker Gilead Sciences Inc
for infringing a patent in a dispute over a blockbuster
hepatitis C treatment.
The justices declined to take up Merck's appeal of a lower
court's ruling that overturned the massive damages verdict after
finding that Merck's patent was invalid.
(Reporting by Andrew Chung in New York; Editing by Will Dunham)